

CORRECTION

Open Access



Correction: CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Fei Xing¹, Hongli Gao¹, Guanglei Chen¹, Lisha Sun¹, Jiayi Sun¹, Xinbo Qiao¹, Jinqi Xue¹ and Caigang Liu^{1*}

Correction: *Mol Cancer* 22, 6 (2023)

<https://doi.org/10.1186/s12943-023-01716-y>

Following publication of the original article [1], the authors sincerely acknowledge that an incorrect image panel was inadvertently included in Figure 3F and 4H. To ensure the accuracy and integrity of the article, the authors have carefully reviewed the original data and replaced the erroneous images. This correction does not affect the main findings or conclusions of the study. The revised figures and their corresponding correct captions are provided below.

The original article can be found online at <https://doi.org/10.1186/s12943-023-01716-y>.

*Correspondence:

Caigang Liu
liucg@sj-hospital.org

¹ Department of Oncology, Innovative Cancer Drug Research and Engineering Center of Liaoning Province, Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang 110022, China



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Incorrect Fig. 3 and incorrect caption:




Fig. 3 CMTM6 promotes the survival, migration, invasion and trastuzumab resistance of BC cells in vitro. **A** qRT-PCR and Western blot validated CMTM6 silencing in JIMT-1 cells and CMTM6-overexpression in SKBR3 cells. Negative control (NC) JIMT-1 and SKBR3 cells were transduced with lentivirus for the control shRNA or transfected with the control plasmid, respectively. **B, C** CCK-8 assay determined the viability of the indicated BC cells following treatment with trastuzumab (0–100 µg/ml). **D, E** ethynyl-2'-deoxyuridine (EdU) analysis of the proliferation of CMTM6-silenced JIMT-1 cells, CMTM6 overexpressing SKBR3 cells, control JIMT-1 cells and SKBR3 cells following treatment with trastuzumab (10 µg/ml). (scale bar, 50 µm). **F, G** TUNEL analysis of apoptotic CMTM6-silenced JIMT-1 cells, CMTM6 overexpressing SKBR3 cells, control JIMT-1 and SKBR3 cells following treatment with trastuzumab (10 µg/ml). **H, I** Cell invasion assay revealed that CMTM6 silencing inhibited JIMT-1 cell invasion while CMTM6 overexpression enhanced SKBR3 cell invasion following treatment with trastuzumab (10 µg/ml). (scale bar, 50 µm). Data are representative images or expressed as the mean ± SD of each group from three independent experiments. **P* < 0.05; ***P* < 0.01; ****P* < 0.001

Correct Fig. 3 and correct caption:




Fig. 3 CMTM6 promotes the survival, migration, invasion and trastuzumab resistance of BC cells in vitro. **A** qRT-PCR and Western blot validated CMTM6 silencing in JIMT-1 cells and CMTM6-overexpression in SKBR3 cells. Negative control (NC) JIMT-1 and SKBR3 cells were transduced with lentivirus for the control shRNA or transfected with the control plasmid, respectively. **B, C** CCK-8 assay determined the viability of the indicated BC cells following treatment with trastuzumab (0–100 $\mu\text{g/ml}$). **D, E** ethynyl-2'-deoxyuridine (EdU) analysis of the proliferation of CMTM6-silenced JIMT-1 cells, CMTM6 overexpressing SKBR3 cells, control JIMT-1 cells and SKBR3 cells following treatment with trastuzumab (10 $\mu\text{g/ml}$). (scale bar, 50 μm). **F, G** TUNEL analysis of apoptotic CMTM6-silenced JIMT-1 cells and control JIMT-1 cells following treatment with trastuzumab (10 $\mu\text{g/ml}$). **H, I** Cell invasion assay revealed that CMTM6 silencing inhibited JIMT-1 cell invasion while CMTM6 overexpression enhanced SKBR3 cell invasion following treatment with trastuzumab (10 $\mu\text{g/ml}$). (scale bar, 50 μm). Data are representative images or expressed as the mean \pm SD of each group from three independent experiments. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$

Incorrect Fig. 4 and incorrect caption:




Fig. 4 CMTM6 directly interacts with HER2 and enhancing the HER2 signaling in BC cells. **A** IHC analysis of HER2 protein expression in BC tissues with low or high CMTM6 protein expression (scale bar, 50 μ m). **B** Association between CMTM6 and HER2 protein expression in BC tissues. **C** Western blot analysis of CMTM6 and HER2 protein levels in BC tissues. **D** Correlation between CMTM6 and HER2 protein levels in BC tissues. Data are mean \pm SEM. **E** Confocal microscopy analysis of the subcellular co-localization of CMTM6 (green) and HER2 (red) in JIMT-1 cells, with DAPI nuclear staining (blue) (scale bar, 10 μ m). **F, G** Co-immunoprecipitation revealed the direct interaction between endogenous CMTM6 and HER2 proteins in JIMT-1 cells. **H** Western blot analysis of CMTM6, HER2, p-HER2, PI3K, AKT, MEK, ERK, N-cadherin and E-cadherin protein levels in CMTM6-silenced JIMT-1, CMTM6 overexpressing SKBR3, control JIMT-1 and SKBR3 cells. Data are representative images of each group of cells from three separate experiments

Correct Fig. 4 and correct caption:




Fig. 4 CMTM6 directly interacts with HER2 and enhancing the HER2 signaling in BC cells. **A** IHC analysis of HER2 protein expression in BC tissues with low or high CMTM6 protein expression (scale bar, 50 μ m). **B** Association between CMTM6 and HER2 protein expression in BC tissues. **C** Western blot analysis of CMTM6 and HER2 protein levels in BC tissues. **D** Correlation between CMTM6 and HER2 protein levels in BC tissues. Data are mean \pm SEM. **E** Confocal microscopy analysis of the subcellular co-localization of CMTM6 (green) and HER2 (red) in JIMT-1 cells, with DAPI nuclear staining (blue) (scale bar, 10 μ m). **F, G** Co-immunoprecipitation revealed the direct interaction between endogenous CMTM6 and HER2 proteins in JIMT-1 cells. **H** Western blot analysis of CMTM6, HER2, p-HER2, PI3K, AKT, MEK, ERK, N-cadherin, and E-cadherin protein levels in CMTM6-silenced JIMT-1, CMTM6 overexpressing SKBR3, control JIMT-1 and SKBR3 cells. Data are representative images of each group of cells from three separate experiments.

Published online: 14 April 2025

Reference

- Xing F, Gao H, Chen G, et al. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. *Mol Cancer*. 2023;22:6. <https://doi.org/10.1186/s12943-023-01716-y>.